Development of Immunotherapies Targeting TCR-Vβ2 for Treatment of Cutaneous T Cell Lymphoma

The study explores the development of immunotherapies targeting TCR-Vβ2 for treating cutaneous T cell lymphoma (CTCL). Researchers identified that malignant T cells in CTCL patients often express the TCR-Vβ2, which is not commonly found in healthy T cells. They created anti-Vβ2 chimeric antigen receptor (CAR)-T cells from healthy donor T cells, which were modified to prevent graft-versus-host reactions. These CAR-T cells significantly reduced Vβ2+ cells in a patient-derived xenograft model, demonstrating high on-target killing efficacy with minimal impact on healthy cells. Additionally, a humanized anti-Vβ2 antibody was developed for potential NK cell-mediated therapy, effectively eliminating Vβ2+ cells in vitro and in vivo. This approach offers a promising strategy for more specific and safe treatment of CTCL and other T cell malignancies.